1-Pyrrolidineethanamine, β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-, hydrochloride, hydrate (1:1:1)

421.01578

420.25400

268-472-2

DTXSID5040176

24.94000

5.50580

white powder

91 ±2°

Desiccate at RT

LD50 in mice (mg/kg): 1955 orally, 23.5 i.v. (Mauvernay, 1978)

NONH for all modes of transport

2

UY1162000

|Danger|H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]|P261, P271, P272, P280, P285, P302+P352, P304+P312, P304+P340, P304+P341, P312, P321, P333+P313, P342+P311, P363, and P501|Aggregated GHS information provided by 18 companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)|Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)|A class of drugs that act by selective inhibition of calcium influx through cellular membranes. (See all compounds classified as Calcium Channel Blockers.)|Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)

1978 CERM

Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients